Evidence-Based Treatments for Adults with Migraine
- PMID: 26839703
- PMCID: PMC4709728
- DOI: 10.1155/2015/629382
Evidence-Based Treatments for Adults with Migraine
Abstract
Migraine, a significantly disabling condition, is treated with acute and preventive medications. However, some individuals are refractory to standard treatments. Although there is a host of alternative management options available, these are not always backed by strong evidence. In fact, most of the drugs used in migraine were initially designed for other purposes. Whilst effective, the benefits from these medications are modest, reflecting the need for newer and migraine-specific therapeutic agents. In recent years, we have witnessed the emergence of novel treatments, of which noninvasive neuromodulation appears to be the most attractive given its ease of use and excellent tolerability profile. This paper reviews the evidence behind the available treatments for migraine.
Similar articles
-
The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10. Headache. 2019. PMID: 30536394
-
Migraine: integrated approaches to clinical management and emerging treatments.Lancet. 2021 Apr 17;397(10283):1505-1518. doi: 10.1016/S0140-6736(20)32342-4. Epub 2021 Mar 25. Lancet. 2021. PMID: 33773612 Review.
-
Neuromodulation in migraine.Handb Clin Neurol. 2024;199:179-200. doi: 10.1016/B978-0-12-823357-3.00003-3. Handb Clin Neurol. 2024. PMID: 38307646 Review.
-
Noninvasive Neuromodulation in Headache: An Update.Neurol India. 2021 Mar-Apr;69(12 Suppl 1):S183-S193. doi: 10.4103/0028-3886.315998. Neurol India. 2021. PMID: 34003164 Review.
-
Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.Headache. 2018 May;58(5):700-714. doi: 10.1111/head.13275. Epub 2018 Feb 15. Headache. 2018. PMID: 29446063
Cited by
-
Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients.Med Devices (Auckl). 2016 May 30;9:131-7. doi: 10.2147/MDER.S105899. eCollection 2016. Med Devices (Auckl). 2016. PMID: 27313479 Free PMC article.
-
Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment.Mol Diagn Ther. 2019 Dec;23(6):681-694. doi: 10.1007/s40291-019-00428-8. Mol Diagn Ther. 2019. PMID: 31612314 Review.
-
Factors Associated with Over-the-Counter Analgesic Overuse among Individuals Experiencing Headache.Clin Pract. 2022 Sep 5;12(5):714-722. doi: 10.3390/clinpract12050074. Clin Pract. 2022. PMID: 36136868 Free PMC article.
-
Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs.Patient Prefer Adherence. 2017 Jan 19;11:121-129. doi: 10.2147/PPA.S125137. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 28176899 Free PMC article.
-
Can Pulsed Radiofrequency of the Occipital Nerves Cause Sedation? A New Perspective of Existing Knowledge.Anesth Pain Med. 2020 Apr 13;10(2):e96418. doi: 10.5812/aapm.96418. eCollection 2020 Apr. Anesth Pain Med. 2020. PMID: 32754427 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources